Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Lancet Psychiatry. 2019 Dec;6(12):977-979. doi: 10.1016/S2215-0366(19)30394-3. Epub 2019 Nov 1.

Author

Erick H Turner¹

Affiliation

¹ Behavioral Health and Neurosciences Division, Portland Veterans Affairs Medical Center, Portland, OR 97239, USA; Department of Psychiatry, Oregon Health and Science University, Portland, OR, USA. Electronic address: [email protected].

PMID: 31680014
DOI: 10.1016/S2215-0366(19)30394-3

No abstract available

MeSH terms

Clinical Trials as Topic*
Depressive Disorder, Treatment-Resistant / drug therapy*
Humans
Ketamine / therapeutic use*
Treatment Outcome*
United States
United States Food and Drug Administration / standards*

Substances

Esketamine
Ketamine